Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The claim is directly supported by FDA labeling in Warnings and Precautions (5.1), Geriatric Use (8.5), and Patient Counseling (17), including the increased mortality statement and inclusion of ZYPREXA/olanzapine-treated patients.
Category Scores
Accurate Statements
Increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs (including ZYPREXA/olanzapine).
Supported by label language in 5.1 (Elderly Patients with Dementia-Related Psychosis: Increased Mortality), 8.5 (Geriatric Use), and 17 (Patient Counseling Information).
ZYPREXA/olanzapine-treated elderly patients with dementia-related psychosis have increased risk of death compared with placebo, with higher death incidence in placebo-controlled trials (3.5% vs 1.5%).
Supported by 5.1 and reiterated in 8.5.
Unsupported Statements
Contradictions
Important Omissions
The claim does not mention the label’s additional context that ZYPREXA is not approved for dementia-related psychosis treatment (explicitly stated in 5.1, 8.5, and 17).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statement reflects an FDA-labeled boxed warning/precaution about increased mortality risk in the specified population and does not instruct use in an off-label way.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of the label’s explicit statement that ZYPREXA is not approved for elderly patients with dementia-related psychosis.
Suggested Improvement
Add the labeling qualifier that ZYPREXA is not approved for the treatment of dementia-related psychosis (as stated in 5.1, 8.5, and 17).